131 related articles for article (PubMed ID: 29069746)
1. WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects.
Guan F; Ding R; Zhang Q; Chen W; Li F; Long L; Li W; Li L; Yang D; Xie L; Yuan S; Wang L
Oncotarget; 2017 Sep; 8(42):71782-71796. PubMed ID: 29069746
[TBL] [Abstract][Full Text] [Related]
2. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
3. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.
Nicholson B; Lloyd GK; Miller BR; Palladino MA; Kiso Y; Hayashi Y; Neuteboom ST
Anticancer Drugs; 2006 Jan; 17(1):25-31. PubMed ID: 16317287
[TBL] [Abstract][Full Text] [Related]
4. A novel colchicine-based microtubule inhibitor exhibits potent antitumor activity by inducing mitochondrial mediated apoptosis in MIA PaCa-2 pancreatic cancer cells.
Kumar A; Singh B; Mahajan G; Sharma PR; Bharate SB; Mintoo MJ; Mondhe DM
Tumour Biol; 2016 Oct; 37(10):13121-13136. PubMed ID: 27449046
[TBL] [Abstract][Full Text] [Related]
5. 5-(Furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3H-1,2-dithiol-3-one oxime (6f), a new synthetic compound, causes human fibrosarcoma HT-1080 cell apoptosis by disrupting tubulin polymerisation and inducing G2/M arrest.
Zuo D; Pang L; Shen J; Guan Q; Bai Z; Zhang H; Li Y; Lu G; Zhang W; Wu Y
Int J Oncol; 2017 Jun; 50(6):2069-2078. PubMed ID: 28440465
[TBL] [Abstract][Full Text] [Related]
6. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
Meng F; Cai X; Duan J; Matteucci MG; Hart CP
Cancer Chemother Pharmacol; 2008 May; 61(6):953-63. PubMed ID: 17639393
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
8. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
9. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
Kasibhatla S; Baichwal V; Cai SX; Roth B; Skvortsova I; Skvortsov S; Lukas P; English NM; Sirisoma N; Drewe J; Pervin A; Tseng B; Carlson RO; Pleiman CM
Cancer Res; 2007 Jun; 67(12):5865-71. PubMed ID: 17575155
[TBL] [Abstract][Full Text] [Related]
10. DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080.
Qiao F; Zuo D; Shen X; Qi H; Wang H; Zhang W; Wu Y
Cancer Chemother Pharmacol; 2012 Aug; 70(2):259-70. PubMed ID: 22752214
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel vinyl sulfone derivatives as anti-tumor agents with microtubule polymerization inhibitory and vascular disrupting activities.
Li W; Yin Y; Yao H; Shuai W; Sun H; Xu S; Liu J; Yao H; Zhu Z; Xu J
Eur J Med Chem; 2018 Sep; 157():1068-1080. PubMed ID: 30176537
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors.
Cao D; Liu Y; Yan W; Wang C; Bai P; Wang T; Tang M; Wang X; Yang Z; Ma B; Ma L; Lei L; Wang F; Xu B; Zhou Y; Yang T; Chen L
J Med Chem; 2016 Jun; 59(12):5721-39. PubMed ID: 27213819
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel 1-indolyl acetate-5-nitroimidazole derivatives of combretastatin A-4 as potential tubulin polymerization inhibitors.
Yao YF; Wang ZC; Wu SY; Li QF; Yu C; Liang XY; Lv PC; Duan YT; Zhu HL
Biochem Pharmacol; 2017 Aug; 137():10-28. PubMed ID: 28456516
[TBL] [Abstract][Full Text] [Related]
14. A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity.
Zheng YB; Gong JH; Liu XJ; Wu SY; Li Y; Xu XD; Shang BY; Zhou JM; Zhu ZL; Si SY; Zhen YS
Sci Rep; 2016 Aug; 6():31472. PubMed ID: 27510727
[TBL] [Abstract][Full Text] [Related]
15. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
Wang F; Yang Z; Liu Y; Ma L; Wu Y; He L; Shao M; Yu K; Wu W; Pu Y; Nie C; Chen L
Bioorg Med Chem; 2015 Jul; 23(13):3337-50. PubMed ID: 25937236
[TBL] [Abstract][Full Text] [Related]
17. DHPAC, a novel synthetic microtubule destabilizing agent, possess high anti-tumor activity in vincristine-resistant oral epidermoid carcinoma in vitro and in vivo.
Zhang Y; Gong FL; Lu ZN; Wang HY; Cheng YN; Liu ZP; Yu LG; Zhang HH; Guo XL
Int J Biochem Cell Biol; 2017 Dec; 93():1-11. PubMed ID: 29074436
[TBL] [Abstract][Full Text] [Related]
18. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
[TBL] [Abstract][Full Text] [Related]
19. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
Canela MD; Noppen S; Bueno O; Prota AE; Bargsten K; Sáez-Calvo G; Jimeno ML; Benkheil M; Ribatti D; Velázquez S; Camarasa MJ; Díaz JF; Steinmetz MO; Priego EM; Pérez-Pérez MJ; Liekens S
Oncotarget; 2017 Feb; 8(9):14325-14342. PubMed ID: 27224920
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
